Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 34, Numéro 5, Mai 2018
|
|
|---|---|---|
| Page(s) | 391 - 394 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/20183405007 | |
| Publié en ligne | 13 juin 2018 | |
- Chung RT, Baumert TF. Curing chronic hepatitis C: the arc of a medical triumph. N Engl J Med 2014 ; 370 : 1576–1578. [Google Scholar]
- El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012 ; 142 : 1264–1273.e1. [CrossRef] [PubMed] [Google Scholar]
- Mailly L, Zeisel MB, Baumert TF. Enfermé dehors ! Traitement de l’hépatite C chronique par un inhibiteur d’entrée. Med Sci (Paris) 2015 ; 31 : 1075–1077. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Baumert TF, Juhling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017 ; 15 : 52. [CrossRef] [PubMed] [Google Scholar]
- El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011 ; 365 : 1118–1127. [Google Scholar]
- Hoshida Y, Fuchs BC, Bardeesy N, et al. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014 ; 61 : S79–S90. [CrossRef] [PubMed] [Google Scholar]
- El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 2016 ; 64 : 130–137. [CrossRef] [PubMed] [Google Scholar]
- Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology 2016 ; 64 : 1818–1819. [CrossRef] [PubMed] [Google Scholar]
- van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012 ; 308 : 2584–2593. [CrossRef] [PubMed] [Google Scholar]
- European association for the study of the liver; European organisation for research and treatment of cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 : 908–43. [Google Scholar]
- Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016 ; 65 : 727–733. [CrossRef] [PubMed] [Google Scholar]
- Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016 ; 65 : 719–726. [CrossRef] [PubMed] [Google Scholar]
- ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016 ; 65 : 734–740. [CrossRef] [PubMed] [Google Scholar]
- Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017 ; 153 : 996–1005.e1. [CrossRef] [PubMed] [Google Scholar]
- van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017 ; 66 : 485–493. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.